Autoantibodies to ion channels at the neuromuscular junction

Autoimmunity Reviews

Volumn 2, Issue 2, 2003, Pages 94-100

  Lang, Bethan ^a   Vincent, Angela ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Acquired neuromyotonia; Autoimmune; Lambert Eaton myasthenic syndrome; Myasthenia gravis; Neuromuscular junction

Indexed keywords

AUTOANTIBODY; CALCIUM CHANNEL; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PHOSPHOTRANSFERASE; TUMOR ANTIGEN; VOLTAGE GATED POTASSIUM CHANNEL; ION CHANNEL;

ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE ASSOCIATION; EATON LAMBERT SYNDROME; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LUNG SMALL CELL CANCER; MUSCLE FIBER MEMBRANE; MYASTHENIA GRAVIS; MYOKYMIA; NEUROLOGIC DISEASE; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PLASMAPHERESIS; POSTSYNAPTIC MEMBRANE; REVIEW; THYMOMA; TISSUE SPECIFICITY; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY;

ANIMALS; AUTOANTIBODIES; HUMANS; ION CHANNELS; ISAACS SYNDROME; LAMBERT-EATON MYASTHENIC SYNDROME; MODELS, BIOLOGICAL; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION;

EID: 0141888945     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(02)00146-5     Document Type: Review

References (26)

1. Drachman D.B. Myasthenia gravis. N Engl J Med. 298:1978;136-142.
2. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 10:2002;797-804.
3. Romi F., Bo L., Skeie G.O., et al. Titin and ryanodine epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol. 128:2002;82-89.
4. Buckley C., Willcox N., Newsom-Davis J., Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology. 57:2001;1579-1582.
5. Engel A.G. Myasthenia gravis and myasthenic syndromes. Ann Neurol. 16:1984;519-534.
6. Engel A.G., Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann NY Acad Sci. 505:1987;326-332.
7. Toyka K.V., Drachman D.B., Griffin D.E., et al. Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 296:1977;125-131.
8. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 48:1985;1246-1252.
9. Engel A.G., Ohno K. Congenital myasthenic syndromes. Adv Neurol. 88:2002;203-215.
10. Blaes F., Beeson D., Plested P., Lang B., Vincent A. IgG from 'seronegative' myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Ann Neurol. 47:2000;504-510.
11. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 7:2001;365-368.
12. Plested C.P., Tang T., Spreadbury I., Littleton E.T., Kishore U., Vincent A. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology. 59:2002;1682-1688.
13. O'Neill J.H., Murray N.M., Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 111:1988;577-596.
14. Benatar M., Blaes F., Johnston I., et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimmunol. 113:2001;153-162.
15. Maddison P., Newsom-Davis J., Mills K.R., Souhamis R.L. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small cell lung carcinoma. Lancet. 353:1999;117-118.
16. Fugunaga H., Engel A.G., Lang B., et al. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci. 80:1983;7636-7640.
17. Oguro-Okano M., Griesmann G., Wieben E., et al. Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc. 67:1992;1150-1159.
18. Motamura M., Lang B., Johnston I., Palace J., Vincent A., Newsom-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel antibodies in Lambert-Eaton myasthenic syndrome. J Neurol Sci. 147:1997;35-42.
19. Mason W., Graus F., Lang B., et al. Small cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 120:1997;1279-1300.
20. Graus F., Lang B., Pozo-Rosich P., Saiz A., Casamitjana R., Vincent A. P/Q type calcium channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 59:2002;764-766.
21. Newsom-Davis J., Mills K.R. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain. 116:1993;453-469.
22. + channels of peripheral nerves. Ann Neurol. 38:1995;714-722.
23. Nagado T., Arimura K., Sonoda Y., et al. Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain. 122:1999;2057-2066.
24. + channels are implicated in neuromyotonia. Ann Neurol. 41:1997;238-246.
25. Liguori R., Vincent A., Clover L., et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain. 124:2001;2417-2426.
26. Buckley C., Oger J., Clover L., et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 50:2001;74-79.